Il trattamento del carcinoma della prostata in fase di resistenza alla castrazione Giuseppe Procopio, MD, Treatment options for patients with CRPC Zoledronic Acid1 Sipuleucel-T3 Cabazitaxel4 Docetaxel2 2002 2004 . . . . . . . . . . . . . . . Denosumab5 . . 2010 Abiraterone6 2011 The near future MDV3100 7 Alpharadin8 1Saad et al. J Natl Cancer Inst 2002; 94: 1458–1468 et al. N Engl J Med 2004;351(15): 1502-1512 3Kantoff et al. N Engl J Med 2010; 363(5): 411-422 4de Bono et al. Lancet. 2010; 376(9747): 1147-1154 5Fizazi et al. Lancet 2011; 377(9768): 813-822 2Tannock 6de Bono et al. N Engl J Med 2011; 346(21): 1995-2005 7Scher HI et al. N Engl J Med. 2012 Aug 15. 8 ] Parker C. et al. ESMO 2011: Abstract 2, and ASCO GU 2012 Prostate Cancer Clinical States Noncastrate Castration resistant Diagnoses: 217,730 Clinically Localized Disease Rising PSA Deaths: 32,050 Clinical Metastases: Noncastrate Rising PSA: Castrate Clinical Clinical Metastases: Metastases: Castrate Castrate Pre- 1st-Line Provenge Docetaxel Clinical Metastases: Castrate PostCabazitaxel Abiraterone MDV3011 Radium 223 With detectable metastases: deaths from cancer exceed those from other causes Modified from Scher and Heller. Urology. 2000. TAX 327 Updated Survival Analysis Probability of Survival 1.0 Docetaxel q3wk Docetaxel qwk Mitoxantrone q3wk 0.8 Median survival (months) Docetaxel q3wk: 19.2 Docetaxel qwk: 17.8 Mitoxantrone q3wk 16.3 0.6 0.4 Hazard ratio 0.79 0.87 – P-value 0.004 0.086 – 0.2 0.0 0 1 2 3 4 5 6 7 Years Berthold DR et al. J Clin Oncol. 2008;26:242-245. Tannock I. N Engl J Med. 2004;351:1502-1512. Phase III Trials Docetaxel plus for CRPC • • • • • • • • Oblimersen sodium1 OGX-0112 Bevacizumab Aflibercept Lenalidomide6 Dasatinib3 Atrasentan4 1. Sternberg CN et al. Ann Oncol. 2009 Jul;20(7):1264-9 Zibotentan5 2 .Chi KN et al, J Clin Oncol. 2010 Sep 20;28(27):4247-54 3. Araujo JC et al, Cancer. 2012 Jan 1;118(1):63-71 4.Quinn DI, J Clin Oncol 30, 2012 (suppl; abstr 4511) 5.Trump DL, Prostate. 2011 Sep;71(12):1264-75 6. Petrylak D et al, ESMO 2012 LBA24. Overall Survival with 2nd line Chemotherapy for mCRPC Treatment Setting Patients (N) Response and overall survival 950 Median OS: 14.3 months vs 14.3 months HR = 0.98 p = 0.7999 755 Median OS: 15.1 months vs 12.7 months HR = 0.72 p<.0001 SPARC Satraplatin + prednisone vs Placebo + prednisone Progression after 1 prior chemotherapy regimen TROPIC Cabazitaxel + prednisone vs Mitoxantrone + prednisone Prior Docetaxel Sternberg CN, et al. J Clin Oncol 2009;27:5431−8 de Bono J, et al. Lancet. 2010 Oct 2;376(9747):1147-54 TROPIC: Study Design (n=720) mCRPC Progression after docetaxel • Stratification factor : – ECOG PS (0,1 vs 2) – Measurable/nonmeasurable • Primary Endpoint: – Overall survival (OS) • Secondary Endpoint: – PSA response, PSA progression, PFS, RR, pain progression, safety, PK of cabazitaxel R R A A N N D D O O M M I I Z Z E E n=360 Cabazitaxel 25mg/m2 q3w Prednisone 10mg qd Mitoxantrone 12mg/m2 q3w Prednisone 10mg qd n=360 Reduction of 25% in the risk of death or median OS=10.67 months for cabazitaxel vs 8 months 511 events, duration 36 months de Bono et al. Lancet 2010; 376(9747): 1147-1154 Cabazitaxel Approved as Second-Line Chemotherapy 30% reduction in risk of death Median OS, Mos MP CBZP 12.7 15.1 HR 0.70 95% CI 0.59-0.83 p value <0.0001 Combined median follow-up: 12.8 months de Bono et al. Lancet 2010; 376(9747): 1147-1154 Androgen biosynthesis inhibitors: Abiraterone, TAK700 2nd generation AR inhibitors: MDV3100, ARN509 Chen Y, et al. Lancet Oncol. 2009;10:981-991. Abiraterone Inhibits Androgen Biosynthesis Through CYP17 • Androgens produced at 3 critical sites – Testes – Adrenal gland – Prostate tumor cells • Abiraterone inhibits biosynthesis of androgens that stimulate tumor cell growth • PSA and radiographic responses in Phase 2 studies of CRPC – Chemo-naïve and post-chemo patients1-6 1. Attard G et al. J Clin Oncol. 2008;26:4563-4571; 2. Attard G et al. J Clin Oncol. 2009;27:3742-3748; 3. Reid AH et al. J Clin Oncol. 2010;28:1489-1495; 4. Ryan CJ et al. J Clin Oncol. 2010;28:1481-1488; 5. Danila DC et al. J Clin Oncol. 2010;28:1496-1501; 6. de Bono JS et al. Ann Oncol. 2010;21(suppl 8): Abstract LBA5. Abiraterone Acetate Phase III Post-Chemo Study Design Efficacy endpoints (ITT) • 1195 patients progressive mCRPC • Failed 1 or 2 chemotherapy regimens, 1 with docetaxel R A N D O M I Z E D Abiraterone 1000 mg daily Prednisone 5 mg bid n = 797 2:1 Placebo daily Prednisone 5 mg bid n = 398 1° endpoint: • OS (25% improvement; HR 0.8) 2nd endpoints: • TTPP • rPFS • PSA response • Phase 3 multicenter, randomized, double-blind, placebo-controlled study (147 sites in 13 countries; USA, Europe, Australia, Canada) • Stratification by: ECOG performance status 0-1 vs 2 Worst pain over previous 24 hours BPI short form; 0-3 (absent) vs 4-10 (present) Prior chemotherapy 1 vs 2 Type of progression PSA only vs radiographic with or without PSA de Bono JS et al. N Engl J Med. 2011;364:1995-2005 Overall Survival: Second Pre-planned Analysis Median benefit 4.6 months 100 HR =0.74 (0.638-0.859) P<0.0001 26% reduction in risk of death Survival (%) 80 AA median OS (95% CI): 15.8 months (14.82-17.02) 60 40 Placebo median OS (95% CI): 11.2 months (10.41-13.14) 20 Placebo AA Median follow-up 20.2 months 0 0 AA 797 Placebo 398 6 657 306 12 18 24 Time to Death (Months) 473 273 15 183 6 100 30 0 0 Scher HI et al. J Clin Oncol 2011; 29 (suppl): LBA4517 Fizazi K et al, Lancet Oncol, in press Adverse Events of Special Interest AA (n = 791) All Grades Grades 3/4 Placebo (n = 394) All Grades Grades 3/4 Fluid retention 30.5% 2.3% 22.3% 1.0% Hypokalemia 17.1% 3.8% 8.4% 0.8% LFT abnormalities 10.4% 3.5% 8.1% 3.0% Hypertension 9.7% 1.3% 7.9% 0.3% Cardiac disordersa 13.3% 4.1% 10.4% 2.3% aMost frequently reported cardiac terms were tachycardia and atrial fibrillation. The rate of grade 5 lethal cardiac events was identical in the 2 study arms: 1.3% (10 pts) in AA and 1.3% (5 pts) in placebo. MDV3100 (Enzalutamide, XTANDI) • Oral drug rationally designed to target AR signaling, impacting multiple steps in AR signaling pathway. T T 1 Enzalutamide Inhibits Binding of Androgens to AR AR • No demonstrated agonist effects in preclinical models. Cell cytoplasm 2 Inhibits Nuclear Translocation of AR Cell nucleus 3 Tran et al. Science 2009;324:787–90. And Uniquely AR Inhibits Association Of AR with DNA 14 5 AFFIRM Phase III Trial Design Patient Population: 1199 patients with progressive CRPC *Failed docetaxel chemotherapy R A N D O M I Z E D Enzalutamide 160 mg daily n = 800 Placebo n = 399 2:1 Corticosteroids were not required, but allowed Stratification: PS and BPI score, PCWG2 criteria used 156 centers from 15 countries and 5 continents September 2009 - November 2010 Primary Endpoint: Overall Survival 90% power to detect a 24% reduction in mortality Enzalutamide Overall Survival Median benefit 4.8 months HR = 0.631 (0.529, 0.752) P <0.0001 37% reduction in risk of death Enzalutamide: 18.4 months (95% CI: 17.3, NYR) Placebo: 13.6 months (95% CI: 11.3, 15.8) enzalutamide 800 775 701 627 400 211 72 7 0 Placebo 399 376 317 263 167 81 33 3 0 Scher HI et al. N Engl J Med. 2012 Aug 15, Sternberg CN et al. Global Can Prost, Brussels June 2012 Survival Benefit Across All Subgroups Hazard Ratio for Death Overall Survival median (mo) Enzalutamide / Placebo (95% CI) Favors Enzalutamide* Favors Placebo* Scher HI et al. N Engl J Med. 2012 Aug 15, Sternberg CN et al. Global Can Prost, Brussels June 2012 Adverse Events of Special Interest Grade ≥3 Events All Grades Enzalutamide (n = 800) Placebo (n = 399) Enzalutamide (n = 800) Placebo (n = 399) Fatigue 33.6% 29.1% 6.3% 7.3% Cardiac Disorders 6.1% 7.5% 0.9% 2.0% Myocardial Infarction 0.3% 0.5% 0.3% 0.5% LFT Abnormalities* 1.0% 1.5% 0.4% 0.8% Seizure 0.6% 0.0% 0.6% 0.0% *Inchyperbilirubinemia, AST increased, ALT increased, LFT abnormal, transaminases increased, and blood bilirubin increased. FDA-ApprovedcAugust 31, 2012 Radium-223 Targets Bone Metastases Range of alpha-particle Radium-223 Bone surface • Alpha-particles induce double-strand DNA breaks in adjacent tumour cells1 • Short penetration of alpha emitters (2-10 cell diameters) = highly localised tumour cell killing and minimal damage to surrounding normal tissue 1. Perez et al. Principles and Practice of Radiation Oncology. 5th ed. Lippincott Williams & Wilkins; 2007:103. ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) Phase III Study Design PATIENTS • Confirmed symptomatic CRPC • ≥ 2 bone metastases • No known visceral metastases STRATIFICATION • Total ALP: < 220 U/L vs ≥ 220 U/L • Bisphosphonate use: Yes vs No • Prior docetaxel: Yes vs No • Postdocetaxel or unfit for docetaxel TREATMENT R A N D O M I S E D 6 injections at 4-week intervals Radium-223 (50 kBq/kg) + Best standard of care Placebo (saline) + Best standard of care 2:1 N = 921 Planned follow-up is 3 years Clinicaltrials.gov identifier: NCT00699751 Parker C, ESMO 2011 and ASCO 2012 ALSYMPCA Updated Analysis Time To First SRE* 100 HR = 0.636 90 95% CI, 0.519, 0.780 80 P = 0.0001 70 60 % Radium-223, n = 614 Median: 12.2 months 50 40 30 Placebo, n = 307 Median: 6.7 months 20 10 0 Month 0 3 6 9 12 15 18 21 24 27 30 Radium-223 614 487 332 193 125 62 31 8 8 1 0 Placebo 307 207 108 51 33 17 8 6 3 1 0 *Provisional data Parker C, ASCO 2012 ALSYMPCA Updated Analysis Overall Survival 100 90 HR = 0.695 80 95% CI, 0.581, 0.832 70 P = 0.00007 60 % 50 Radium-223, n = 614 Median OS: 14.9 months 40 30 20 Placebo, n = 307 Median OS: 11.3 months 10 0 Month 0 3 6 9 12 15 18 21 24 27 30 33 36 39 Radium-223 614 578 504 369 274 178 105 60 41 18 7 1 0 0 Placebo 307 288 228 157 103 67 39 24 14 7 4 2 1 0 Parker C, ASCO 2012 OS Benefit in Recent CRPC Trials Trial/ Agent Mechanism Comparator Survival (months) Hazard Ratio P-value AFFIRM Enzalutamide Androgen Receptor Signaling Inhibitor Placebo 18.4 vs. 13.6 0.631 <0.0001 COU-AA-301 Abiraterone + prednisone CYP17 Inhibitor Placebo + prednisone 14.8 vs. 10.9 0.646 <0.0001 Cytotoxic Mitoxantrone + prednisone 15.1 vs. 12.7 0.70 <0.0001 Alpha-particle emitting radionuclide Placebo 14.9 vs 11.3 0.69 0.0018 TROPIC Cabazitaxel + prednisone ALSYMPCA Radium 223* * Only 60% of these patients were post-docetaxel patients Clinical Need in CRPC Pre - Chemotherapy • An intervention with little or no toxicity compared with chemotherapy for treatment of asymptomatic or mildly symptomatic CRPC • Aim to prevent or delay the onset of pain related to metastatic disease and disease progression • Prolong survival Overall Study Design of COU-AA-302 Patients • Progressive chemonaïve mCRPC patients (Planned N = 1088) • Asymptomatic or mildly symptomatic R A N D O M I Z E D Efficacy end points AA 1000 mg daily Prednisone 5 mg BID (Actual n = 546) Placebo daily Prednisone 5 mg BID (Actual n = 542) 1:1 Co-Primary: • rPFS by central review • OS Secondary: • Time to opiate use (cancer-related pain) • Time to initiation of chemotherapy • Time to ECOG-PS deterioration • TTPP • Phase 3 multicenter, randomized, double-blind, placebo-controlled study conducted at 151 sites in 12 countries; USA, Europe, Australia, Canada • Stratification by ECOG performance status 0 vs 1 25 25 25 PRESENTED PRESENTEDAT AT Abiraterone Doubled Time to rPFS Subjects Without Progression or Death (%) 100 Abiraterone (median, mos): 16.5 Prednisone (median, mos): 8.3 HR (95% CI): 80 p Value: 0.53 (0.45-0.62) < 0.0001 60 40 20 0 Abiraterone Prednisone 0 3 6 9 12 15 18 21 24 27 Months From Randomization Abiraterone 546 485 389 311 240 195 157 131 117 Prednisone 542 406 244 176 133 99 78 62 45 IA3 data. rPFS assessed by investigator review at prespecified IA. 30 66 20 20 7 33 36 4 0 0 0 Rathkopf et al. ASCO GU 2013; Abstract 5 (Oral Presentation) OS Favors Abiraterone Subjects Without Death (%) 100 Abiraterone (median, mos): 35.3 Prednisone (median, mos): 30.1 HR (95% CI): p Valuea: 0.79 (0.66-0.95) 0.0151 80 60 40 20 0 Abiraterone Prednisone 12 15 18 21 24 27 30 33 36 Months From Randomization Abiraterone 546 538 524 503 482 452 421 393 333 175 68 15 0 Prednisone 542 534 508 492 465 437 400 361 283 153 67 9 0 IA3 data. aPrespecified significance level by O’Brien-Fleming Boundary Rathkopf et al. ASCO GU 2013; Abstract 5 (Oral Presentation) 0 3 6 9 Subsequent Therapy Was Common Abiraterone (n = 419) n (%) Prednisone (n = 482) n (%) 274 (65) 347 (72) Docetaxel 239 (57) 304 (63) Cabazitaxel 60 (14) 70 (15) Ketoconazole 39 (9) 63 (13) Abirateroneb 38 (9) 78 (16) Sipuleucel-T 33 (8) 28 (6) No. with selected subsequent therapy for mCRPCa aFirst patient crossover after unblinding on 7 May 2012. IA3 data clinical cutof f date on 22 May 2012. bPrior to unblinding (eg. not per protocol). IA3 data. Rathkopf et al. ASCO GU 2013; Abstract 5 (Oral Presentation) Maximal Decline From Baseline (%) Abiraterone Doubled the Maximal Decline in PSA (≥ 50%) Relative to Prednisone Alone Abiraterone Prednisone 100 75 50 25 0 -25 -50 -75 -100 • 29% of patients in the prednisone control arm had a decline in PSA of ≥ 50% • 69% of patients in the abiraterone arm had a decline in PSA of ≥ 50% IA3 data. A negative percent indicates a decline in PSA. A positive percent indicates that the subject never has a decline in PSA. Rathkopf et al. ASCO GU 2013; Abstract 5 (Oral Presentation) TAK 700 : Pre-Chemo Study Bone scan flare up in patient with decrease PSA Pre treatment : January 23 2012 PSA 80 mildly symptomatic Week 13: April 14, 2012 PSA 49 asymptomatic What’s next? Cabozantinib (XL-184) in mCRPC Baseline 12 weeks Cabozantinib Dual inhibition MET VEGFR2 74% Soft tissue lesion regression 19% Docetaxel-pretreated patients Complete resolution of bone metastases (similar results obtained in docetaxal-naïve patients) 56% *Partial response or stable disease †Randomization stopped due to cabozantinib efficacy PFS, progression-free survival Partial resolution of bone metastases Hussain M, et al. J Clin Oncol. 2011;29(15S): Abst 4516 Change in Bone Scan Lesion Area Patients with ≥1 post-baseline bone scan (n = 84) Prior therapies: Docetaxel Docetaxel + Abiraterone or MDV3100 C Cabazitaxel Radionuclide C C 100 +++ % Change from Baseline 80 60 * 40 20 CC 0 C C C ** CC CC CC CC C **C C C -20 -40 -60 -80 -100 Median change in bone scan lesion area: 60% reduction Smith M et al, ASCO 2012 Abst #4513 New Agents and Trials for CRPC • • • • • • • • Tasquinimod • OGX-0113 • Abiraterone4 Abiraterone • Dasatinib • Cabazitaxel5 Sipuleucel-T1 • Aflibercept • MDV31006 PROSTVAC2 • Ipilimumab MDV3100 • TAK-700 Ipilimumab • Alpharadin7 Alpharadin7 • Cabozantinib TAK-700 1Kantoff PW, N Engl J Med. 2010 Jul 29;363(5):411-22,2Kantoff PW, J Clin Oncol 2010; 28:1099–105 3CHi KN, J Clin Oncol; 28:4247-4254, 4 de Bono JS et al. N Engl J Med. 2011;364:1995-2005, 5 de Bono et al. Lancet 2010; 376(9747): 1147-1154, 6Scher HI et al. N Engl J Med. 2012 Aug 15. 7Parker C et al, ESMO LBA 2 and ASCO 2012 Progress and Conclusions in mCRPC • Unequivocal evidence of continued involvement of the AR signaling axis • Non toxic therapies pre-chemotherapy of interest • Need to address prostate cancer heterogeneity to move the field forward • Need to evaluate the best sequence and combination of agents Conclusioni Prospettive per il paziente mCRPC Miglioramento sopravvivenza Riduzione degli eventi scheletrici Miglioramento della quality of life Thank you for your attention and your kind invitation